2-fluoro-2-deoxyglucose-6-phosphate and Cerebellar-Diseases

2-fluoro-2-deoxyglucose-6-phosphate has been researched along with Cerebellar-Diseases* in 1 studies

Trials

1 trial(s) available for 2-fluoro-2-deoxyglucose-6-phosphate and Cerebellar-Diseases

ArticleYear
Precuneus and Cingulate Cortex Atrophy and Hypometabolism in Patients with Alzheimer's Disease and Mild Cognitive Impairment: MRI and (18)F-FDG PET Quantitative Analysis Using FreeSurfer.
    BioMed research international, 2015, Volume: 2015

    The objective of this study was to compare glucose metabolism and atrophy, in the precuneus and cingulate cortex, in patients with Alzheimer's disease (AD) and mild cognitive impairment (MCI), using FreeSurfer.. 47 individuals (17 patients with AD, 17 patients with amnestic MCI, and 13 healthy controls (HC)) were included. MRI and PET images using (18)F-FDG (mean injected dose of 185 MBq) were acquired and analyzed using FreeSurfer to define regions of interest in the hippocampus, amygdala, precuneus, and anterior and posterior cingulate cortex. Regional volumes were generated. PET images were registered to the T1-weighted MRI images and regional uptake normalized by cerebellum uptake (SUVr) was measured.. Mean posterior cingulate volume was reduced in MCI and AD. SUVr were different between the three groups: mean precuneus SUVr was 1.02 for AD, 1.09 for MCI, and 1.26 for controls (p < 0.05); mean posterior cingulate SUVr was 0.96, 1.06, and 1.22 for AD, MCI, and controls, respectively (p < 0.05).. We found graduated hypometabolism in the posterior cingulate cortex and the precuneus in prodromal AD (MCI) and AD, whereas atrophy was not significant. This suggests that the use of (18)F-FDG in these two regions could be a neurodegenerative biomarker.

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cerebellar Diseases; Cognitive Dysfunction; Female; Glucose-6-Phosphate; Gyrus Cinguli; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Parietal Lobe; Positron-Emission Tomography; Radiography

2015